Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"Lancet (London, England)"
topic_facet:"Antirheumatic Agents"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22Antirheumatic+Agents%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22Antirheumatic+Agents%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22Lancet+%28London%2C+England%29%22&filter%5B%5D=topic_facet%3A%22Antirheumatic+Agents%22&lookfor=%22Clinical+Trial%2C+Phase+III%22&type=Subject
PubPharm (17)
1
Baricitinib in juvenile idiopathic arthritis : an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
enthalten in:
Lancet (London, England)
| 2023
von
Ramanan, A.
|
Quartier, P.
|
Okamoto, N.
| +105
CommentIn: Lancet. 2023 Aug 12;402(10401):508-509. - PMID 37423229
Wird geladen...
2
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment : a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)
enthalten in:
Lancet (London, England)
| 2023
von
McInnes, I.
|
Asahina, A.
|
Coates, L.
| +13
CommentIn: Lancet. 2023 Jan 7;401(10370):2-3. - PMID 36495880
Wird geladen...
3
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED) : a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
enthalten in:
Lancet (London, England)
| 2020
von
McInnes, I.
|
Behrens, F.
|
Mease, P.
| +13
CommentIn: Lancet. 2020 May 9;395(10235):1463-1465. - PMID 32386578
Wird geladen...
4
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2) : a double-blind, randomised, placebo-controlled phase 3 trial
enthalten in:
Lancet (London, England)
| 2020
von
Mease, P.
|
Rahman, P.
|
Gottlieb, A.
| +10
CommentIn: Lancet. 2020 Apr 4;395(10230):1091-1093. - PMID 32178770
Wird geladen...
5
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1) : a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
enthalten in:
Lancet (London, England)
| 2019
von
van der Heijde, D.
|
Song, I.
|
Pangan, A.
| +10
CommentIn: Lancet. 2019 Dec 7;394(10214):2047-2048. - PMID 31732181
Wird geladen...
6
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY) : a randomised, placebo-controlled, double-blind phase 3 study
enthalten in:
Lancet (London, England)
| 2019
von
Smolen, J.
|
Pangan, A.
|
Emery, P.
| +9
CommentIn: Lancet. 2019 Jun 8;393(10188):2277-2278. - PMID 31180015
Wird geladen...
7
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V) : 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
enthalten in:
Lancet (London, England)
| 2018
von
van der Heijde, D.
|
Cheng-Chung Wei, J.
|
Dougados, M.
| +89
Wird geladen...
8
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND) : a double-blind, randomised controlled phase 3 trial
enthalten in:
Lancet (London, England)
| 2018
von
Genovese, M.
|
Fleischmann, R.
|
Combe, B.
| +7
CommentIn: Lancet. 2018 Jun 23;391(10139):2477-2478. - PMID 29908671
Wird geladen...
9
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT) : a randomised, double-blind, placebo-controlled phase 3 trial
enthalten in:
Lancet (London, England)
| 2018
von
Burmester, G.
|
Kremer, J.
|
Van den Bosch, F.
| +7
CommentIn: Lancet. 2018 Jun 23;391(10139):2477-2478. - PMID 29908671
Wird geladen...
10
Effect of tight control management on Crohn's disease (CALM) : a multicentre, randomised, controlled phase 3 trial
enthalten in:
Lancet (London, England)
| 2017
von
Colombel, J.
|
Panaccione, R.
|
Bossuyt, P.
| +23
CommentIn: Lancet. 2018 Dec 23;390(10114):2742-2744. - PMID 29096947
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: Lancet (London, England)
Filter aufheben
Thema: Antirheumatic Agents
Medienart
17
Aufsätze
15
E-Artikel
15
E-Ressourcen
2
Gedruckte Aufsätze
Zeitschriftentitel
Lancet (London, England)
Thema
Antirheumatic Agents
17
Clinical Trial, Phase III
17
Journal Article
17
Randomized Controlled Trial
16
Multicenter Study
11
Research Support, Non-U.S. Gov't
7
Methotrexate
7
YL5FZ2Y5U1
6
Antibodies, Monoclonal, Humanized
5
Adalimumab
5
Antibodies, Monoclonal
5
FYS6T7F842
5
Janus Kinase Inhibitors
4
4RA0KN46E0
4
Comparative Study
4
Heterocyclic Compounds, 3-Ring
4
Tumor Necrosis Factor-alpha
4
upadacitinib
2
3XC8GUZ6CB
2
9007-41-4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
15
2000-
2
1900-1999
Erscheinungsjahr(e)
Von:
Bis:
Sprache
17
Englisch
Haven't found what you're looking for?
Wird geladen...